Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABADDLF 88 EV-to-EBIT is 23.33 as of Aug. 03, 2026, which is 27% below its 10-year median of 32.10. GuruFocus rates ADDLF with a GF Score™ of 88/100 and a GF Value™ of $15.15. The stock has 5 warning signs investors should review. Among 470 Medical Devices & Instruments companies, AddLife AB ranks worse than 62.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AddLife AB's Enterprise Value for the quarter that ended in Jun. 2026 was $2,406 Mil.
AddLife AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $109 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB EV-to-EBIT Related Terms
AddLife AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AddLife AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AddLife AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AddLife AB's EV-to-EBIT falls into.
AddLife AB's current Enterprise Value is $2,549 Mil.
AddLife AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $109 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB (ADDLF) has a EV-to-EBIT of 23.33 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AddLife AB and its competitors. This is 27% below median its historical median of 32.10. Over the past decade, AddLife AB's EV-to-EBIT has ranged from 19.70 to 53.96. According to the industry distribution chart, AddLife AB ranks #295 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is AddLife AB's EV-to-EBIT too high?
AddLife AB's current EV-to-EBIT of 23.33 is 27% below median its 10-year median of 32.10. Over the past 10 years, this metric has ranged from a low of 19.70 to a high of 53.96. The Medical Devices & Instruments industry median EV-to-EBIT is 18.92. AddLife AB's value of 23.33 is 23.3% above this industry median. Based on the distribution chart, AddLife AB ranks #295 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AddLife AB has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #295 out of 470 companies for EV-to-EBIT. This places AddLife AB in the lower half of its industry. The industry median EV-to-EBIT is 18.92. AddLife AB's value of 23.33 is 23.3% above this benchmark. Historically, AddLife AB's own EV-to-EBIT has ranged from 19.70 to 53.96 over the past decade. While the company's 10-year median is 32.10 vs. the industry median of 18.92, AddLife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.92, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current EV-to-EBIT of 23.33 is 23.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current EV-to-EBIT is 23.33, which is 27% below median its own 10-year median of 32.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (ADDLF) has a current EV-to-EBIT of 23.33. The stock's GF Value™ is $15.15, compared to a current price of $15.75 — trading 4% above its estimated fair value. The current EV-to-EBIT is 23.33, which is 27% below median its 10-year median of 32.10 and 23.3% above the Medical Devices & Instruments industry median of 18.92. AddLife AB's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AddLife AB (ADDLF), the current EV-to-EBIT is 23.33 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (ADDLF) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of $15.75 is trading 4% above its estimated GF Value™ of $15.15.
Key valuation signals for ADDLF:
EV-to-EBIT: 23.33 (27% below median its 10-year median of 32.10)
GF Value™: $15.15 vs. price of $15.75 (4% above fair value)
Industry Position: 23.3% above the Medical Devices & Instruments median (#295 of 470)
No single metric tells the full story. See the ADDLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
88GF Score
Get the complete analysis for ADDLF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADDLF has been successfully added to your 
